Selective ASO-based JAK2 inhibitor for the treatment of hematological malignancies with JAK2 V617F mutation burden. Use of causal modeling to uncover cell-cell communication dynamics in the tumor ...
US pharma major AbbVie and China’s RemeGen today announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational programmed cell ...
In the fight against disease, programmed cell death – also known as apoptosis – is a key protective function of the body. It breaks down cells that are damaged or have undergone dangerous changes.